Aims & Scope
The Journal of Diabetology Research (JODR) is a peer-reviewed, open access diabetes research journal published by Directive Publications. It disseminates rigorous, original scholarship across the full spectrum of diabetology, from the molecular pathophysiology of type 2 diabetes mellitus, insulin resistance and beta-cell dysfunction to the clinical management of glycemic control, diabetic complications and metabolic disease.
The journal welcomes work on prediabetes and incident diabetes, risk-factor epidemiology, diabetes prevention and screening, oral hypoglycemic agents and GLP-1 receptor agonists, diabetic nephropathy and chronic kidney disease, genome-wide association and polygenic studies, drug utilization evaluation, and health-related quality of life. We publish original research, systematic and narrative reviews, clinical case reports, and editorials that bridge bench, bedside and population health.
JODR serves endocrinologists, diabetologists, nephrologists, clinical researchers, public-health scientists, pharmacologists and trainees seeking a trusted, internationally accessible venue. Every submission undergoes double-blind peer review by subject experts.
Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, indexed for discovery via OpenAlex and Google Scholar, and exposed through an OAI-PMH endpoint for harvesting. The journal follows COPE ethical principles, and article-processing charges apply on acceptance with waivers and discounts available.
Subject Coverage
Journal of Diabetology Research welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in Journal of Diabetology Research — explore related research across our journals.
Articles
Real-World Evaluation Of Dapagliflozin And Empagliflozin In Type 2 Diabetes: Cardiorenal And Metabolic Perspectives
Drug utilization evaluation of oral hypoglycemic agents in tertiary care teaching hospital
Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists
Insulin resistance and secretion change after 3 years follow-up and the risk for developing diabetes in non-diabetic adults
Frequently Asked Questions
What topics does the Journal of Diabetology Research cover?
JODR covers the breadth of diabetology: type 2 and type 1 diabetes mellitus, prediabetes and incident diabetes, glycemic control and HbA1c, insulin resistance and secretion, GLP-1 receptor agonists and oral hypoglycemic agents, diabetic nephropathy and chronic kidney disease, genetics and genome-wide association studies, diabetes prevention and screening, drug utilization evaluation, and health-related quality of life in people with diabetes.
Who should publish in and read the Journal of Diabetology Research?
JODR is intended for endocrinologists, diabetologists, nephrologists, clinical and translational researchers, public-health and epidemiology scientists, clinical pharmacologists, and graduate trainees. Anyone investigating the mechanisms, prevention, treatment, or complications of diabetes will find relevant readers and an appropriate venue for their work.
How do I submit a manuscript to the Journal of Diabetology Research?
Prepare your manuscript according to the author guidelines, then submit through the journal's submit page. JODR accepts original research, systematic and narrative reviews, clinical case reports, and editorials on diabetology. Every submission enters double-blind peer review by subject-matter experts.
Is the Journal of Diabetology Research open access, and who holds copyright?
Yes. JODR is fully open access. Accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence, so they are free to read and reuse with attribution, and authors retain copyright to their work.
Does the Journal of Diabetology Research charge article-processing fees, and are waivers available?
An article-processing charge applies only on acceptance, after successful peer review; there are no submission fees. Waivers and discounts are available, particularly for authors from low- and middle-income settings. Contact the editorial office for current charges and waiver eligibility before or during submission.
What type of peer review does the Journal of Diabetology Research use?
JODR operates double-blind peer review, so author and reviewer identities are mutually concealed to support impartial evaluation. The journal follows COPE ethical principles for authorship, conflicts of interest, corrections and retractions.
Will articles in the Journal of Diabetology Research be discoverable and citable?
Yes. Every published article receives a permanent Crossref DOI and is made discoverable through OpenAlex and Google Scholar, with metadata exposed via an OAI-PMH endpoint for harvesting. This ensures stable citation, indexing, and long-term availability of the scholarly record.
Is the Journal of Diabetology Research indexed in DOAJ, PubMed, or Scopus?
As a newer open access title, JODR is currently discoverable via Crossref DOIs, OpenAlex, Google Scholar and its OAI-PMH endpoint. The journal is building its publication record toward eligibility for services such as DOAJ and PubMed Central; it does not yet claim indexing in DOAJ, PubMed, Scopus or Web of Science.